#United States #New York #Class Action #Securities Fraud #Sarepta Therapeutics

Levi & Korsinsky Notifies Sarepta Investors

On July 8, 2025, Levi & Korsinsky, LLP announced an important update for investors of Sarepta Therapeutics, Inc. This notice is aimed at individuals affected by the company's alleged securities fraud. Sarepta Therapeutics, listed under NASDAQ as SRPT, is presently involved in a class action lawsuit that seeks to address significant losses faced by its investors.

Overview of the Lawsuit

The lawsuit targets claims that Sarepta misrepresented critical information regarding its gene therapy product, ELEVIDYS, which is designed for the treatment of Duchenne muscular dystrophy. Investors are encouraged to take notice of this legal action due to the potential implications on investment recovery. Specifically, the complaint outlines several allegations against Sarepta:
1. Safety Risks: The therapy, ELEVIDYS, has allegedly posed considerable safety risks that were not disclosed.
2. Inadequate Trials: Concerns have also been raised about the efficacy of trial protocols failing to identify severe side effects, which could jeopardize patient safety.
3. Regulatory Issues: Due to the aforementioned risks, it is believed that Sarepta may have to cease recruitment for ongoing trials, triggering further regulatory assessments.
4. Misleading Statements: Collectively, the claims suggest a pattern of misleading assurances provided to investors that may have induced financial damages.

Actions for Affected Investors

If you have encountered any losses related to Sarepta's stock between June 22, 2023, and June 24, 2025, you are eligible to apply for the lead plaintiff position in this class action. The deadline for such applications is set for August 25, 2025. It is vital for investors to understand that you don't need to be a lead plaintiff to receive compensation from any potential settlements related to the case.

To participate, potential plaintiffs can visit Levi & Korsinsky's form for further information and assistance. You can also reach out to Joseph E. Levi, Esq. at his email, [email protected], or call him directly at (212) 363-7500.

No Financial Risk Involved

Participation in this class action lawsuit carries no financial burden for investors. Those classified as class members are entitled to potential compensation without any upfront fees or costs. If you're part of this case, you won't bear any individual financial responsibilities for joining the suit.

Levi & Korsinsky's Track Record

Over the last two decades, Levi & Korsinsky has been at the forefront of protecting investor rights, recovering hundreds of millions of dollars for shareholders affected by corporate misconduct. Their experience encompasses a wide array of complex securities litigation, ensuring they possess the knowledge and resources essential for navigating high-stakes legal situations. For seven consecutive years, they have been recognized in ISS Securities Class Action Services' Top 50 Report as leaders in the field of securities litigation in the U.S.

The firm boasts over 70 dedicated professionals committed to supporting clients through these challenging periods. Investors looking to claim their rights and seek restitution against Sarepta's alleged misdeeds are advised to take prompt action under the counsel of this reputable firm.

For any inquiries or additional information related to this case, interested parties can contact Levi & Korsinsky, LLP at:

Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
Email: [email protected]
Phone: (212) 363-7500
Fax: (212) 363-7171
Website: www.zlk.com

This critical update serves as a reminder for investors to stay vigilant about their investments, especially during uncertain times like these. Stay informed, and act swiftly to safeguard your financial interests.